Document is current
Any future updates will be listed below
-
Authors
Tsiachristas, Apostolos
Vallance, Grant
Koleva-Kolarova, Rositsa
Taylor, Harriet
Solomons, Luke
Rizzo, Giovanni
Chaytor, Catherine
Miah, Junel
Wordsworth, Sarah
Hassan, A. Bassim
- License Information
-
More Information
Article History
Received: 8 December 2021
Accepted: 19 April 2022
First Online: 26 April 2022
Declarations
:
: This paper reports a clinical audit within Oxford University Health Foundation Trust (OUHFT) [reference number 14/05/2020-SUWON-FORD] approved by its Directorate Clinical Audit Review Board. The approval of the Directorate Clinical Audit Review Board of Oxford University Health Foundation Trust included that no individual patient required informed consent for this study as all patients undergo OUHFT consent for chemotherapy and ToxNav®testing that includes use of data for audit and service development purposes. All data was anonymised by the data management team (GV). All methods were carried out in accordance with relevant guidelines and regulations (Declaration of Helsinki).
: Not Applicable.
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The data collection, analysis and manuscript preparation was completed independently of Oxford Cancer Biomarkers Ltd. who performed the test.
